Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) with a $13 price target.
August 13, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman maintains a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) with a $13 price target.
The reaffirmation of a Buy rating and a $13 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100